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OBJECTIVES: ACE inhibitors are a potent therapy for
congestive heart failure associated with left ventricular
dysfunction and hypertension. Taking a hospital perspec-
tive, we report an update of a previous analysis of the
health economic consequences of treating these hyper-
tensive patients with enalapril in the Canadian setting.
METHODS: A decision analytic model was used to
project survival probabilities and hospitalization rates
beyond the trial observation period (5 years) using a sec-
ondary analysis of a subset of 1917 hypertensive patients
with or without overt symptoms of congestive heart
failure from the Studies of Left Ventricular Dysfunction
(SoLVD). Patients who had HBP, deﬁned by either an 
elevated systolic (140mmHg) or diastolic (90mmHg)
blood pressure were selected for this study. We updated
the model with Canadian cost inputs for fatal and non-
fatal hospitalization, ambulatory care, death outside of
the hospital, and enalapril for year 2003. Costs and 
beneﬁts were discounted at a 5% annual rate. RESULTS:
Over a projected 5-year period, patients treated primar-
ily with enalapril twice-daily gained 0.18 life-years and
experienced 0.4 fewer hospitalizations per patient com-
pared to those receiving placebo. Over their lifetimes,
patients treated with enalapril were projected to gain 2.14
life-years and experience 0.36 fewer hospitalizations. The
incremental cost-utility ratios for enalapril versus placebo
shown net cost savings of CAN$2309 over 5 years and
CAN$3552 per QALY gained over patients’ lifetimes. For
the subset of patients with overt symptoms of congestive
heart failure, enalapril was cost saving in both the 5-year
and lifetime projections. These results were not sensi-
tive to changes in model parameters. CONCLUSION:
Enalapril treatment for hypertensive patients with left
ventricular dysfunction is projected to extend life ex-
pectancy, reduce hospitalizations, and to be either cost
saving or highly cost-effective in Canada.
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LONG-TERM COST-EFFECTIVENESS OF
PRIMARY ANGIOPLASTY COMPARED TO
FIBRINOLYSIS IN ACUTE MYOCARDIAL
INFARCTION
Sridhar K, Mahon JL
University of Western Ontario, London, ON, Canada
Primary angioplasty (PA) is clinically superior in reduc-
ing the risk of mortality and stroke at 30 days compared
with ﬁbrinolysis. OBJECTIVES: To assess the long-term
incremental cost effectiveness of PA compared with ﬁbri-
nolysis and the overall certainty of the baseline analy-
sis using probabilistic sensitivity analysis. METHODS:
Long-term costs and effects of PA and ﬁbrinolysis were
compared using Markov modeling. Four possible transi-
tion states were included in each arm: remaining asymp-
tomatic, myocardial infarction, revascularization and
dead. Patients could transition between the ﬁrst three
states with cycle intervals set at one year. The “dead”
state was the absorbing state with no further transition.
Transition probabilities remained ﬁxed between states
throughout the cycles. The termination condition was 
set a ten cycles or years. Costs for the transition states
included direct costs and estimates of productivity losses.
Outcomes were derived from available clinical literature.
Discount rates were 5% for costs and 3% for beneﬁts
over time. The incremental cost effectiveness ratio was
obtained at the end of 10 cycles. Parameter distributions
were created to reﬂect the overall uncertainty of the point
estimates for clinical outcomes and costs, which were
included in the probabilistic analysis. Monte Carlo simu-
lation using 1,000 sample trials was performed for the
probabilistic analysis. RESULTS: After 10 years, the
model predicted the total mortality with PA would be
20.9% (2.1% annualized) compared with 30.3% (3%
annualized) in the ﬁbrinolysis arm. Cumulative reinfarc-
tions would be 11.5% in the primary angioplasty arm
and 20.3% in the ﬁbrinolysis arm. Cumulative rates for
revascularization would be 65% in the primary angio-
plasty arm and 51.9% in the thrombolysis arm. Proba-
bilistic sensitivity analysis suggested that in nearly 80%
of sample clinical trials, PA was economically dominant
over ﬁbrinolysis. CONCLUSIONS: The model predicts
that PA would be dominant and will have a lower rate of
long-term mortality and myocardial infarction, but with
more revascularization procedures compared with 
ﬁbrinolysis.
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SWITCHING PATIENTS TO ROSUVASTATIN
FROM ATORVASTATIN OR OTHER STATINS IS
COST-EFFECTIVE: PHARMACOECONOMIC
ANALYSIS OF MERCURY I
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OBJECTIVE: To assess the cost-effectiveness of switch-
ing patients from atorvastatin (ATV), simvastatin (SIM)
or pravastatin (PRA) to rosuvastatin (Crestor®; RSV),
from the perspective of a UK primary health care
provider. METHODS: The clinical beneﬁt assessed was
the proportion of patients treated to the European Ath-
erosclerosis Society low-density lipoprotein cholesterol
(LDL-C) goal (<3mmol/L). Clinical data were taken from
Measuring Effective Reductions in Cholesterol Using
